## The Ohio State University Wexner Medical Center James Molecular Laboratory Director: Weiqiang Zhao, MD, PhD; CAP# 7194091; CLIA # 36D1046162

Date Requested:	OSU Account #	:U70214	Internal
Name:		Date of Birth:	Sex: □ M □ F
Last First Specimen Collection Date: Time:	MI Patient ID:	Outside block I	D#
Biopsy Site (write in/check):			
Fixative (check one); $\square$ 10% Formalin $\square$ N/A $\square$ Other:	-		
Clinical Indication (required):			⊔ Myeloma ⊔ RO CICL ⊔ RO MPI
□ RO MDS □ T-NHL □ Brain Tumor/Glioma □ Bone □		-	
Clinic Name:Physician:			
*Prior to ordering any germline genetic testing on the patient, the me authorized representative) as required by applicable state law and/or	-	d above has obtained an oral or signed,	written consent from the patient (or their
Contact Person:Phon	e:	Result to Fax or Email:	
Sample requirements: Peripheral blood: purple (EDTA); 3-5	ml preferred. Bone l	Marrow: purple/green; 0.5-1 ml as	pirate, 0.25 minimum.
FFPE FISH: 1 H/E + 2 unstained @ 4 micron <b>positively cha</b>	rged/coated slide pe	r stain. FFPE Molecular: Block or	1 HE/10 unstained @ 10 micron non
coated slide. Fresh Tissue: call (614) 293-0665. All samples	—— must have 2 identifie	ers and accompanying Pathology i	report (Preliminary OK). Ship
Blood/BM immediately on ice pack; if draw is on a Friday or	_		· · · · · · · · · · · · · · · · · · ·
Ship to: JML Molecular Lab, 2001 Polaris Parkway, Room 1	-		v 614 266 0120
Multi-test panels are in italics. CPT coding and test information	on at https://pathol	logy.osu.edu/divisions/Clinical	/molpath/default.ntm
Cancer PCR/Sequencing Tests	·	netic Testing (Germline)	
☐ BCR-ABL1 t(9:22), quantitative PCR		SMA Gene Dosage Analysis	_
□ P190 (prior positive only) □ P210 (prior positive on	• .	Factor V/Leiden  Prothrombin	
☐ BRAF Mutation Analysis, Exon 15/V600 (Blood/BM/FF		Hereditary Hemochromatosis/HFE	(Blood)
☐ BTK and PLCG2, Comprehensive Mutation Profiling (B		Huntington's disease	Companies Analysis
☐ BTK Resistance Mutation (BTK C481S only)		Myotonic Dystrophy (DM1/DMPK	.) Comprehensive Analysis
☐ CALR Mutation Analysis		SMN1/SMN2 DNA Sequencing	
<ul><li>☐ CEBPA Mutation Analysis</li><li>☐ Colon Cancer Mutation Panel (COLMOL) (NGS, FFPE)</li></ul>	Fluc	orescence in situ hybridization (I	FISH) Tests
☐ EGFR Mutation Analysis (exons 19/21, FFPE)		PE only: Block or H&E/3 4um plu	
☐ EGFR T790M mutation analysis (FFPE)		p and 19q, FISH for CNS [block of	
☐ Extended RAS panel: KRAS ex2-4, BRAF 600/601, NRA.		Sp/3q, FISH (Renal cancer)	7 110021 <u>0</u> 00 <u>2 unz</u> j
☐ FLT3 ITD/TKD Mutation Analysis (Blood, BM)	5 6.1.2, 5	ALK, FISH (NSCLC or Lymphom	a)
☐ Hematologic Neoplasm Mutation Panel (Tissue-FFPE, Blo		BCL2, FISH	,
☐ CLL/B-LPD ☐ AML/MDS/MPN	ou/ B111, 1105)	BCL6, FISH	
☐ T-cell LPD ☐ High-grade B-LPD		CCND1 (cyclin D1), FISH	
☐ IDH1 and IDH2 Mutations (Blood, BM, FFPE)		DDIT3 (CHOP), FISH	
☐ IGH/B-cell Gene Rearrangement, PCR		EGFR, FISH (CNS)	
☐ IGVH Somatic Hypermutation (Blood/BM)		EWSR1 (EWS), FISH	
☐ JAK2 V617 Mutation Analysis (Blood/BM/tissue)	□ F	FGFR1, FISH (Lung, SQCA)	
☐ Lung Cancer Biomarker Panel/PULMOL (FFPE)	□ F	HER2, FISH	
[PULNGS & ALK IHC & MET/ROS/RET FISH; submit b	носк ошуј	High-grade lymphoma [BCL2, BC	
$\square$ PD-L1 IHC (22C3, Keytruda)		ung cancer FISH panel [ALK, M	ET, ROS, RET, need 8 US]
☐ Lung Cancer NGS Mutation Panel only (PULNGS) (NG	3, 111 L)	MALT1, FISH (lymphoma)	
☐ Microsatellite Instability (MSI) test only (*tumor & norm	iai ')	MDM2, FISH	
☐ MGMT Promoter methylation, Tumor (FFPE)		MET, FISH	
☐ MLH1 Promoter Methylation, Tumor (FFPE)		MYC, FISH	
☐ MMR IHC ( <i>MLH1</i> , <i>PMS2</i> , <i>MSH2</i> , <i>MSH6</i> ) (FFPE)		RET, FISH ☐ ROS1, FISH	
$\square$ NPM1 mutation ddPCR (Types A, B and D only)		SS18 (SYT1), FISH	
☐ PML-RARA, quantitative PCR (APLQ, Blood/BM)		XY, FISH	
$\square$ TCRB and TCRG PCR (T-cell clonality)	Cor	mments	
$\square$ TCRB only $\square$ TCRG only			